BiotechTube

Haloperidol 10 mg Tablets (Cord Laboratories) + Haldol 10 mg Tablets (McNeil Pharmaceuticals)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psychosis

Conditions

Psychosis

Trial Timeline

Apr 1, 1987 → May 1, 1987

NCT ID
NCT00946491

About Haloperidol 10 mg Tablets (Cord Laboratories) + Haldol 10 mg Tablets (McNeil Pharmaceuticals)

Haloperidol 10 mg Tablets (Cord Laboratories) + Haldol 10 mg Tablets (McNeil Pharmaceuticals) is a phase 1 stage product being developed by Sandoz Group for Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00946491. Target conditions include Psychosis.

What happened to similar drugs?

3 of 17 similar drugs in Psychosis were approved

Approved (3) Terminated (1) Active (14)
🔄Paliperidone ERJohnson & JohnsonPhase 3
🔄Quetiapine FumarateAstraZenecaPhase 3
🔄Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3
🔄Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3
✅ZiprasidonePfizerApproved
✅ziprasidone + Standard therapyPfizerApproved
🔄Xanomeline/trospiumBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00946491Phase 1Completed

Competing Products

20 competing products in Psychosis

See all competitors
ProductCompanyStageHype Score
Paliperidone ERJohnson & JohnsonPhase 3
40
Saracatinib + Placebo Oral TabletAstraZenecaPhase 1
25
Quetiapine FumarateAstraZenecaPhase 3
40
Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3
40
Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3
40
SCH 900460MerckPre-clinical
26
ZiprasidonePfizerApproved
43
ziprasidone + Standard therapyPfizerApproved
35
ziprasidonePfizerPre-clinical
26
Xanomeline/trospiumBristol Myers SquibbPhase 3
47
Memantine + PlaceboLundbeckPhase 1
33
Cannabidiol (CBD) + PlaceboJazz PharmaceuticalsPhase 3
44
Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + PlaceboAcadia PharmaceuticalsPhase 3
37
PimavanserinAcadia PharmaceuticalsApproved
40
pimavanserin tartrate + placeboAcadia PharmaceuticalsPhase 3
37
Placebo + Pimavanserin 34 mg + Pimavanserin 20 mgAcadia PharmaceuticalsPhase 3
37
ACP-204 + PlaceboAcadia PharmaceuticalsPhase 2/3
42
pimavanserin tartrate (ACP-103)Acadia PharmaceuticalsPhase 2
32
Pimavanserin tartrate + PlaceboAcadia PharmaceuticalsPhase 2
32
ACP-204Acadia PharmaceuticalsPhase 3
44